SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis

Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30

In August 2026, Co-Diagnostics, Inc. (the "Company") entered into a material transfer agreem

Two full laboratory installations completed in Florida; installation and customer training underway

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Predict

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s

On September 2, 2026, Co-Diagnostics, Inc. (the "Company") and Brian Brown, the Company’s Ch

Localized cloud environment is designed to support ongoing clinical studies and establish the digita

Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base repre

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stake

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

On Thursday, Co-Diagnostics (NASDAQ:CODX) discussed second-quarter financial results during its earn

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst cons

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expan

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro

Merck and Wellcome-backed Hilleman will manufacture Bundibugyo Ebola vaccine doses for clinical tria

SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the C

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ®

Co-Diagnostics advances its Ebola testing capabilities, sending Bundibugyo virus test kits for evalu

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans

PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India SALT LAKE CITY, July

Co-Diagnostics' India joint venture CoSara has started clinical studies for its rapid TB PCR tes

SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the C

Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner Work

More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 2

Co-Diagnostics completed clinical and analytical studies for its PCR Flu A/B & RSV test and plan

Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in hono

Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding men

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regio

Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regio

 Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnost

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD

Co-Diagnostics shares jump 28% following a $3.0M private placement and key progress on its Bundibugy